Market Overview:
The global plasminogen activator inhibitor market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of cardiovascular diseases, rising geriatric population, and technological advancements in the field of medical care. By type, PAI-1 segment is expected to dominate the market during the forecast period owing to its high usage in medical care applications. By application, medical care segment is anticipated to hold a dominant position during the forecast period as it helps in treating various disorders such as heart attack and stroke.
Product Definition:
A plasminogen activator inhibitor is a substance that inhibits the action of a plasminogen activator. Plasminogen activators are enzymes that break down the fibrin meshwork in blood clots, and inhibitors may be used therapeutically to dissolve blood clots.
PAI-1:
Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of the fibrinolytic system. It was initially identified as an abundant protein in human plasminogen activators and has since been characterized as a member of the serine protease inhibitors family. PAI-1 is found at high levels in patients suffering from cardiovascular diseases, renal failure or other disorders that affect blood clotting.
TIMP-1:
TIMP-1, also known as tissue inimodulin, is a small peptide with insulin-like activity. It is produced by many tissues and cells in response to injury or stress. In humans, it has been shown to be an independent risk factor for the development of heart disease and stroke. Increasing incidences of cardiovascular diseases have led researchers to study potential risk factors that may be modifiable for therapeutic purposes.
Application Insights:
The medical care segment dominated the global plasminogen activator inhibitor market in terms of revenue in 2017. This is due to the rising prevalence of chronic diseases, such as diabetes and cardiovascular diseases. According to a study published by WHO, it was estimated that globally around 9% of population aged over 60 years have some form of disability or chronic disease. In addition, another study reported that around 1-2% of population in developed countries suffer from mobility impairment due to physical disability or frailty. These factors are expected to increase demand for advanced therapeutics which includes PAI-1 inhibitors during the forecast period thus driving growth during the forecast period.
Plasminogen activators are used for various indications including acute lung injury (ALI), acute kidney injury (AKI), sepsis, shock state associated with burns and trauma & critical illness states where there is an increased risk of complications arising from fibrinolysis such as hypoperfusion/hypoxia.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key players, developed healthcare infrastructure, and high awareness levels coupled with relatively higher disposable income. The region is expected to maintain its dominance throughout the forecast period due to increasing demand for advanced therapeutics for treatment of diseases such as Alzheimer’s disease, Parkinson's disease, and others.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising geriatric population base that requires long-term therapies resulting in increased demand for plasminogen activators inhibitors. In addition, growing medical tourism industry supported by low procedural costs & affordability along with improving healthcare facilities will drive regional growth further. ‰˜˜˜˜˜™‰¥‰¤‹È…“;) (Upper Case Italicized Text).
Growth Factors:
- Increasing incidence of cardiovascular diseases: The increasing incidence of cardiovascular diseases is one of the key growth drivers for the plasminogen activator inhibitor market. According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2012, accounting for 31% of all global deaths. This number is projected to increase to 23.3 million by 2030. The growing prevalence of CVDs is thus expected to drive demand for plasminogen activator inhibitors in the coming years.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive demand for plasminogen activator inhibitors in the coming years. According to estimates, the number of people aged 60 or above will exceed 2 billion by 2050, accounting for nearly one-third of the world’s population. This growing geriatric population is more susceptible to age-related disorders such as CVDs and therefore, there will be a corresponding increase in demand for plasminogen activator inhibitors products over time..
Scope Of The Report
Report Attributes
Report Details
Report Title
Plasminogen Activator Inhibitor Market Research Report
By Type
PAI-1, TIMP-1
By Application
Medical Care, Others
By Companies
Bayer AG, SteadyMed, GlaxoSmithKline, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Plasminogen Activator Inhibitor Market Report Segments:
The global Plasminogen Activator Inhibitor market is segmented on the basis of:
Types
PAI-1, TIMP-1
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Medical Care, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer AG
- SteadyMed
- GlaxoSmithKline
- Pfizer
Highlights of The Plasminogen Activator Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PAI-1
- TIMP-1
- By Application:
- Medical Care
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Plasminogen Activator Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Plasminogen activator inhibitor (PAI) is a type of medication that blocks the action of plasminogen, a protein that helps blood to clot. PAIs are used to treat heart attacks, stroke, and other conditions in which clots can form in the blood.
Some of the major companies in the plasminogen activator inhibitor market are Bayer AG, SteadyMed, GlaxoSmithKline, Pfizer.
The plasminogen activator inhibitor market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Plasminogen Activator Inhibitor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Plasminogen Activator Inhibitor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Plasminogen Activator Inhibitor Market - Supply Chain
4.5. Global Plasminogen Activator Inhibitor Market Forecast
4.5.1. Plasminogen Activator Inhibitor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Plasminogen Activator Inhibitor Market Size (000 Units) and Y-o-Y Growth
4.5.3. Plasminogen Activator Inhibitor Market Absolute $ Opportunity
5. Global Plasminogen Activator Inhibitor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Plasminogen Activator Inhibitor Market Size and Volume Forecast by Type
5.3.1. PAI-1
5.3.2. TIMP-1
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Plasminogen Activator Inhibitor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Plasminogen Activator Inhibitor Market Size and Volume Forecast by Application
6.3.1. Medical Care
6.3.2. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Plasminogen Activator Inhibitor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Plasminogen Activator Inhibitor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Plasminogen Activator Inhibitor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Plasminogen Activator Inhibitor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Plasminogen Activator Inhibitor Demand Share Forecast, 2019-2026
9. North America Plasminogen Activator Inhibitor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Plasminogen Activator Inhibitor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Plasminogen Activator Inhibitor Market Size and Volume Forecast by Application
9.4.1. Medical Care
9.4.2. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Plasminogen Activator Inhibitor Market Size and Volume Forecast by Type
9.7.1. PAI-1
9.7.2. TIMP-1
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Plasminogen Activator Inhibitor Demand Share Forecast, 2019-2026
10. Latin America Plasminogen Activator Inhibitor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Plasminogen Activator Inhibitor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Plasminogen Activator Inhibitor Market Size and Volume Forecast by Application
10.4.1. Medical Care
10.4.2. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Plasminogen Activator Inhibitor Market Size and Volume Forecast by Type
10.7.1. PAI-1
10.7.2. TIMP-1
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Plasminogen Activator Inhibitor Demand Share Forecast, 2019-2026
11. Europe Plasminogen Activator Inhibitor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Plasminogen Activator Inhibitor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Plasminogen Activator Inhibitor Market Size and Volume Forecast by Application
11.4.1. Medical Care
11.4.2. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Plasminogen Activator Inhibitor Market Size and Volume Forecast by Type
11.7.1. PAI-1
11.7.2. TIMP-1
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Plasminogen Activator Inhibitor Demand Share, 2019-2026
12. Asia Pacific Plasminogen Activator Inhibitor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Plasminogen Activator Inhibitor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Plasminogen Activator Inhibitor Market Size and Volume Forecast by Application
12.4.1. Medical Care
12.4.2. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Plasminogen Activator Inhibitor Market Size and Volume Forecast by Type
12.7.1. PAI-1
12.7.2. TIMP-1
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Plasminogen Activator Inhibitor Demand Share, 2019-2026
13. Middle East & Africa Plasminogen Activator Inhibitor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Plasminogen Activator Inhibitor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Plasminogen Activator Inhibitor Market Size and Volume Forecast by Application
13.4.1. Medical Care
13.4.2. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Plasminogen Activator Inhibitor Market Size and Volume Forecast by Type
13.7.1. PAI-1
13.7.2. TIMP-1
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Plasminogen Activator Inhibitor Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Plasminogen Activator Inhibitor Market: Market Share Analysis
14.2. Plasminogen Activator Inhibitor Distributors and Customers
14.3. Plasminogen Activator Inhibitor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer AG
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. SteadyMed
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Pfizer
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
